John Fox, MD: What’s interesting is that there are several ways of controlling healthcare costs. One is by controlling the cost of the services that are provided. The other is just preventing people from getting access to those services. I think we have a debate right now where we have to answer that question. As a just and caring society, are we going to provide access to everyone or are we going to say that the only way to limit healthcare costs is to prevent some people from having access to it?
Elizabeth Carpenter: I don’t think members of Congress are having this philosophical debate right now—just to throw that out there.
John Fox, MD: What do you think they’re talking about?
Elizabeth Carpenter: I think they’re talking about the fact that they promised to repeal and replace the Affordable Care Act, and it’s been a campaign issue for 6 years. Now, they’re in charge, and it’s time to deliver. And it’s proving a challenge because—as our president pointed out—healthcare is complicated and personal, as you are all articulating right now.
Robert Carlson, MD: I think all of us at this table have known that healthcare is really complicated for a long time. I would hope that our legislative representatives understand that they have a responsibility to their constituents, both those who voted for them and those who didn’t, and that it’s really about the contract they should have with our citizenry—with all Americans. Americans should not die because they don’t have access to the basics of healthcare. And I don’t think we’re even talking about what I would call premium healthcare—just the basics of healthcare.
Elizabeth Carpenter: And one of the things that I certainly think gets delivered to cancer patients under the Affordable Care Act is the required maximum out-of-pocket limit. That’s something for in-network covered services that applies not just in the markets that we talk about—in the individual market—but also in the commercial market. More than 10% of employer plans prior to the ACA didn’t have a maximum out-of-pocket limit, which obviously makes care in these instances unaffordable for individuals and they have to choose between other necessities and their health. And I think that is a balance Washington continues to face.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More